Neurostimulation in Anxiety Disorders, Post-traumatic Stress Disorder, and Obsessive-Compulsive Disorder

Freire, Rafael C.; Cabrera-Abreu, Casimiro; Milev, Roumen

doi:10.1007/978-981-32-9705-0_18

Cited by 37 publications

(34 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first was a chart review on 26 military veterans with a diagnosis of both PTSD and MDD. While there was significant improvement in depressive symptoms only 35% of the patient group showed small improvement (20%) in their PTSD symptoms 22 . In the other retrospective review the use of bilateral ECT led to significant improvements of both PTSD and MDD symptoms in subjects.…”

Section: Ect and Its Use In Ptsdmentioning

confidence: 89%

“…We found a letter to an editor of an ECT journal that recorded acute clinical improvement in three patients, with refractory OCD and major depressive disorder (MDD), treated with ECT 21 . We found one publication that summarised up‐to‐date findings for its use in post‐traumatic stress disorder (PTSD) 22 …”

Section: Methodsmentioning

confidence: 99%

“…There were some studies before this date but no RCTs. There are two retrospective studies and an open‐label trial where participants may have experienced some benefit in their PTSD symptoms 22 . The first was a chart review on 26 military veterans with a diagnosis of both PTSD and MDD.…”

Section: Ect and Its Use In Ptsdmentioning

confidence: 99%

“…In the other retrospective review the use of bilateral ECT led to significant improvements of both PTSD and MDD symptoms in subjects. In the open‐label study 20 patients with a diagnosis of refractory PTSD received six bilateral treatments, showed improvement (34% reduction) in their CAPS score and also a reduction in their MDD scores by 51% 22 . The CAPS is a 30‐item clinician‐administered assessment tool used to measure PTSD symptoms 22 .…”

Section: Ect and Its Use In Ptsdmentioning

confidence: 99%

See 3 more Smart Citations

Electroconvulsive therapy for refractory anxiety disorders

Yahya

Khawaja

2021

Prog Neurol Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Ect and Its Use In Ptsdmentioning

confidence: 89%

Section: Methodsmentioning

confidence: 99%

Section: Ect and Its Use In Ptsdmentioning

confidence: 99%

Section: Ect and Its Use In Ptsdmentioning

confidence: 99%

See 2 more Smart Citations

Electroconvulsive therapy for refractory anxiety disorders

Yahya

Khawaja

2021

Prog Neurol Psychiatry

View full text Add to dashboard Cite

show abstract

“…Nowadays anxiety disorders are among wide-spread diseases (Bahi et al 2019). Some of the most significant ones for clinical practice are general anxiety disorder, post-traumatic stress disorder, panic disorder (Carpenter et al 2018;Freire et al 2020), obsessive-compulsive disorder, social anxiety disorders, and mixed anxiety-depressive disorder. The attributes of clinical picture of patients with those pathologies are a gradual decrease in communicative and cognitive skills (Nechita et al 2018), as well as disturbance of motivation, motor and vegetative spheres.…”

Section: Introductionmentioning

confidence: 99%

Influence of Diazepino[1,2-a]benzimidazole derivative (DAB-19) on behavioral aspects of animals

Maltsev¹,

Spasov²,

Мирошников³

et al. 2020

RRP

View full text Add to dashboard Cite

Introduction: Diazepino[1,2-a]benzimidazole derivatives showed anxiolytic (EPM, L/D box, Vogel test), antidepressant (Tail Suspension test, Porsolt test), anticonvulsant (Pentylenetetrazole-Induced seizures) and analgesic (Tail-Flick, Hot Plate) actions, which were described earlier (Spasov et al. 2020). 11-(4-tert-butylbenzyl)-2,3,4,5-tetrahydro[1,3]diazepino[1,2-a]benzimidazole hydrobromide (compound DAB-19) has evident anxiolytic, antidepressant and anticonvulsant effects. In the present study, compound DAB-19 was screened for its influence on animals` behavior patterns, such as aggression, obsessive-compulsive behavior, emotional lability, and unsociability. Materials and methods: 112 outbred white animals (rats and mice) were used. Compound DAB-19 (2.34 mg/kg, p.o.) and diazepam (2 mg/kg, p.o.) were injected to the treatment groups. Using an Open Field (OF) test, we evaluated a spontaneous motor activity, a search activity of mice and a degree of their emotionality. During a Marble Burying (MB) test, we monitored anxiolytic and anticompulsive effects of DAB-19. Using a Resident-intruder (RI) test, we evaluated a degree of aggression in the experimental animals, properties of their social interaction, as well as defensive and individual behavior. Results and discussion: Compound DAB-19 has positive influence on the search activity, mood stabilizing activity and antiaggressive actions. Administration of both DAB-19 (2.34 mg/kg, p.o.) and diazepam (2 mg/kg, p.o.) reduced anxiety-like behavior in OP, RI and MB tests, as indicated by a significantly increased number of entries to the center of OP; a decreased number of marbles buried in MB and reduced aggressive behavior in RI. It was stated that using DAB-19 leads to a decrease in affective reactions of the animals – aggression, obsessive-compulsive behavior, neurotic condition and emotional instability. Conclusions: The compound (DAB-19) produces anxiolytic-like effects, compared with those of diazepam, in various anxiety paradigms.

show abstract

The Story of Ferumoxytol: Synthesis Production, Current Clinical Applications, and Therapeutic Potential

Long,

Li,

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Ferumoxytol, approved by the U.S. Food and Drug Administration in 2009, is one of the intravenous iron oxide nanoparticles authorized for the treatment of iron deficiency in chronic kidney disease and end‐stage renal disease. With its exceptional magnetic properties, catalytic activity, and immune activity, as well as good biocompatibility and safety, ferumoxytol has gained significant recognition in various biomedical diagnoses and treatments. Unlike most existing reviews on this topic, this review primarily focuses on the recent clinical and preclinical advances of ferumoxytol in disease treatment, spanning anemia, cancer, infectious inflammatory diseases, regenerative medicine application, magnetic stimulation for neural modulation, etc. Additionally, the newly discovered mechanisms associated with the biological effects of ferumoxytol are discussed, including its magnetic, catalytic, and immunomodulatory properties. Finally, the summary and future prospects concerning the treatment and application of ferumoxytol‐based nanotherapeutics are presented.

show abstract

Neurostimulation in Anxiety Disorders, Post-traumatic Stress Disorder, and Obsessive-Compulsive Disorder

Cited by 37 publications

References 51 publications

Electroconvulsive therapy for refractory anxiety disorders

Electroconvulsive therapy for refractory anxiety disorders

Influence of Diazepino[1,2-a]benzimidazole derivative (DAB-19) on behavioral aspects of animals

The Story of Ferumoxytol: Synthesis Production, Current Clinical Applications, and Therapeutic Potential

Contact Info

Product

Resources

About